<DOC>
	<DOC>NCT02296853</DOC>
	<brief_summary>This study will evaluate the single-dose pharmacokinetics of tenofovir alafenamide (TAF) and it's metabolite tenofovir (TFV) along with the safety and tolerability of TAF in participants with normal hepatic function and severe hepatic impairment.</brief_summary>
	<brief_title>Pharmacokinetics of Tenofovir Alafenamide in Adults With Normal Hepatic Function and Severe Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Screening labs within defined thresholds Creatinine clearance must be â‰¥ 60 mL/min Females who are pregnant or nursing or males who have a pregnant partner Infection with hepatitis B virus (HBV) or HIV History of clinically significant illness (including psychiatric or cardiac) or any other medical disorder that may interfere with participant treatment and/or adherence to the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Severe Hepatic Impairment</keyword>
</DOC>